Cervical cancer immunotherapy: facts and hopes

L Ferrall, KY Lin, RBS Roden, CF Hung, TC Wu - Clinical Cancer Research, 2021 - AACR
It is a sad fact that despite being almost completely preventable through human
papillomavirus (HPV) vaccination and screening, cervical cancer remains the fourth most …

CRISPR-Cas9: a preclinical and clinical perspective for the treatment of human diseases

G Sharma, AR Sharma, M Bhattacharya, SS Lee… - Molecular Therapy, 2021 - cell.com
At present, the idea of genome modification has revolutionized the modern therapeutic
research era. Genome modification studies have traveled a long way from gene …

[HTML][HTML] Genital warts: a comprehensive review

VR Yanofsky, RV Patel… - The Journal of clinical and …, 2012 - ncbi.nlm.nih.gov
External genital warts, also known as condylomata acuminata, are extremely common, with
between 500,000 to one million new cases diagnosed each year in the United States alone …

An armamentarium of wart treatments

MM Lipke - Clinical medicine & research, 2006 - Marshfield Clinic
Patients and clinicians experience the frustration of cutaneous viral warts caused by
infection with the human papilloma virus (HPV). Warts appear in various forms on different …

Plantar warts: epidemiology, pathophysiology, and clinical management

DJ Witchey, NB Witchey, MM Roth-Kauffman… - Journal of Osteopathic …, 2018 - degruyter.com
Verrucae plantaris (plantar warts) are common cutaneous lesions of the plantar aspect of the
foot that are caused by the human papillomavirus (HPV). Ubiquitous in our environment …

HPV-associated diseases

S Ljubojevic, M Skerlev - Clinics in dermatology, 2014 - Elsevier
Nearly 200 distinct human papilloma viruses (HPVs) have now been recognized, and each
is associated with a specific set of clinical lesions. They are associated with a spectrum of …

Development of DNA vaccine targeting E6 and E7 proteins of human papillomavirus 16 (HPV16) and HPV18 for immunotherapy in combination with recombinant …

S Peng, L Ferrall, S Gaillard, C Wang, WY Chi… - MBio, 2021 - Am Soc Microbiol
Immunotherapy for cervical cancer should target high-risk human papillomavirus types 16
and 18, which cause 50% and 20% of cervical cancers, respectively. Here, we describe the …

Human papillomavirus prevalence and type distribution in male anogenital sites and semen

CM Nielson, R Flores, RB Harris, M Abrahamsen… - … Biomarkers & Prevention, 2007 - AACR
Background: Human papillomavirus (HPV) is sexually transmitted and causes cervical
cancer. Although HPV can infect men and women, little is known about infection in men …

Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches

S Sanami, F Azadegan-Dehkordi… - Scientific Reports, 2021 - nature.com
Cervical cancer, caused by human papillomavirus (HPV), is the fourth most common type of
cancer among women worldwide. While HPV prophylactic vaccines are available, they have …

Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women

NA Hessol, EA Holly, JT Efird, H Minkoff, K Schowalter… - Aids, 2009 - journals.lww.com
Objectives: To study anal intraepithelial neoplasia and its associations with anal and
cervical human papillomavirus (HPV), cervical neoplasia, host immune status, and …